Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Bortezomib in Relapsed Refractory Multiple Myeloma
NCT00464178Phase 2Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Apr 2007
- Primary completion
- Feb 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Started Apr 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00464178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00464178.